GLP-1 agonists also improve cardiovascular outcomes in patients with type 2 diabetes or obesity, a benefit not consistently demonstrated for berberine
GLP-1RA Reward Behaviour Systematic Review (PubMed, 2024) GLP-1 Receptor Signalling in Reward Circuitry, Dopamine, and Addiction Research A systematic review of GLP-1 receptor agonist effects on reward behaviour published on PubMed following PRISMA guidelines across OVID, PubMed, Scopus, and Google Scholar evaluated the evidence for GLP-1Rs role in reward dysfunction across obesity, type 2 diabetes, and psychiatric conditions
How We Reviewed These 22 Telehealth Clinics Our 2026 ranking scored each provider on five dimensions: price transparency, FDA-approved medication access, insurance acceptance, state availability, and clinical oversight (US-licensed clinician network, lab-testing protocol, prescribing audit trail)
As we gather more data, clearer guidelines may emerge regarding safe and effective use of these medications alongside IVF treatment
Moreover, we found that GPR17 is expressed in approximately 74% of GLP-1 expressing EECs of the human small intestine [27]
